Advert for Healthcare Professionals Only
I am a patient (Please go to our patient website)
- All Topics
- Allergy and Clinical Immunology
- Anesthesiology
- Angiology
- Cardiology
- Central Nervous System
- Clinical Laboratory
- Complementary and Alternative Medicine
- Critical Care/Intensive Care
- Dermatology
- Diabetes and Endocrinology
- Ear, Nose and Throat
- Emergency Medicine
- Eye Health and Disorders
- Family Medicine
- Gastroenterology
- Gerontology/Geriatrics
- Haematology
- Hepatology
- HIV/AIDS
- Immunology
- Infectious Diseases
- Internal Medicine
- Kidney and Urological Diseases
- Medical Genetics
- Men's Health, Andrology and Urology
- Musculoskeletal Disorders
- Neonatal/Perinatal Medicine
- Neurological Disorders
- Nutrition and Dietetics
- Oncology
- Orthopaedics
- Paediatrics
- Pain Management
- Palliative Medicine
- Plastic Surgery and Aesthetic Medicine
- Podiatry
- Preventive Medicine
- Psychiatry/Mental Health
- Radiology
- Respiratory
- Rheumatology
- Sexual Health
- Sleep Medicine
- Sports Medicine
- Surgery (General)
- Transplantation
- Tropical Medicine
- Vaccines
- Women's Health and Obs/Gyn
- ADHD
- Alzheimer's Disease
- Arthritis
- Atopic Dermatitis
- Cholesterol
- Chronic Myeloid Leukemia
- COPD
- Cystic Fibrosis
- Diabetes
- Gastrointestinal Stromal Tumours
- Hepatitis
- Hypertension
- Insomnia
- Lysosomal Storage Disorders
- Men's Health
- Multiple Sclerosis
- Niemann-Pick type C
- NSCLC
- Opioids and Pain
- Parkinson's Disease
- Post-Myocardial Infarction
- Prostate Cancer
- Renal Anaemia
- Renal Cell Carcinoma
- Soft Tissue Sarcoma
- Third Party Website - Asthma and COPD
- CAPOZIDE TABLETS
- SURMONTIL 10MG AND 25MG TABLETS
- NAPRATEC OP
- COBALIN-H INJECTION
- CARBEX
- CALCIUM RESONIUM 99.934% W/W POWDER FOR ORAL/RECTAL SUSPENSION
- HYPURIN BOVINE ISOPHANE
- HYPURIN BOVINE LENTE
- HYPURIN PORCINE 30/70 MIX CARTRIDGES
- HYPURIN BOVINE ISOPHANE VIALS
- DUKORAL ORAL CHOLERA VACCINE
- OXYNORM LIQUID 5 MG/5 ML ORAL SOLUTION
- DORZOLAMIDE/TIMOLOL EYE DROPS
- FENOFIBRATE 267MG CAPSULES
- TRACRIUM INJECTION
- EXOCIN
- FRAGMIN - TREATMENT OF VTE
- FLUDARABINE PHOSPHATE 50 MG POWDER FOR SOLUTION FOR INJECTION OR INFUSION
- GABITRIL FILM-COATED TABLETS (5 , 10, 15 MG)
- PROTOPIC 0.03% OINTMENT
- XISMOX 60 XL PROLONGED RELEASE TABLETS
- PALLADONE SR CAPSULES
- ZINERYT
- PURI-NETHOL 50 MG TABLETS
- DAKTACORT OINTMENT
- MYLERAN 2 MG FILM-COATED TABLETS
- NEOTIGASON 10MG CAPSULES
- LEUKERAN TABLETS 2 MG
- LANVIS TABLETS 40 MG
- PROVIGIL 100 MG TABLETS, PROVIGIL 200 MG TABLETS
- ADHD
- Alzheimers
- Anxiety Disorders
- Arthritis
- Asthma
- Avonex
- Breast Cancer
- Cervical Cancer
- Cholesterol
- Colorectal Cancer
- Copaxone
- Depression
- Diabetes
- Erectile Dysfunction
- Extavia
- Hypertension
- Insomnia
- Men's Health
- Meningitis
- Migraine
- Pain Management
- Parkinson's
- Pharma News
- Post-MI
- Pregnancy
- Prostate
- Rebif
- Renal anaemia
- Renal Cell Carcinoma
- Thrombosis
- Thromboembolism
- Tysabri
Advert for Healthcare Professionals Only
Latest Drugs
Ear, Nose and Throat Drug Data - A-Z (English)
Drug Class Description
Sympathomimetics (decongestants).Generic Name
GenericDrug Description
Xylometazoline Hydrochloride 0.1% w/vPresentation
Nasal drops, solution The product is a clear, colourless solutionIndications
For the symptomatic relief of nasal congestion, perennial and allergic rhinitis (including hay fever), sinusitisAdult Dosage
Adults and elderly (all indications): 2 or 3 drops in each nostril 2 or 3 times daily.
The drops are suitable for children over 12 years of age.
Route of administration: Nasal use
Child Dosage
Under three months, not recommended; under two years, recommended; under two years, doctor's advice only; over three months, instil one to two drops into each nostril once or twice daily when required. Maximum duration, seven days.Contra Indications
Known hypersensitivity to Otrivine.
Patients with trans-sphenoidal hypophysectomy or surgery exposing the dura mater.
Special Precautions
Patients are advised not to take decongestants for more than seven consecutive days. Otrivine, like other preparations belonging to the same class of active substances, should be used only with caution in patients showing a strong reaction to sympathomimetic agents as evidenced by signs of insomnia, dizziness etc.
- Do not exceed the recommended dosage
- Decongestants should not be used for more than seven consecutive days. If symptoms persist consult your doctor
- If you are pregnant or taking other medicines or are under a doctor's care consult him before using Otrivine
- The adult drops should not be used for infants or children under 12 years
- Each Otrivine pack should be used by one person only to prevent any cross infection
- Some patients who have sensitive nasal passages may feel some local discomfort when applying nasal drops. Other side effects are very rare
- Keep medicines out of reach of children
Adverse Reactions
The following side effects have occasionally been encountered: A burning sensation in the nose and throat, local irritation, nausea, headache, and dryness of the nasal mucosa.
Systemic cardiovascular effects have occurred, and this should be kept in mind when giving Otrivine to people with cardiovascular disease
Manufacturer
Novartis Consumer Health UK LimitedDrug Availability
GSLUpdated
25 March 2009Advert for Healthcare Professionals Only
Latest News
13th February 2012
Cyberknife (Accuray Inc) relieves pain of Trigeminal Neuralgia facial nerve condition Page
Cyberknife, the Intensity Modulated RadioTherapy system from Accuray Inc, can relieve the stabbing pain of the facial nerve condition Trigeminal Neuralgia. Researchers treated 17 patients with Trigeminal Neuralgia with Cyberknife radiosurgery between 2007 and 2009. The patients, who were aged between 36 and 90, had had their symptoms for between one and 11 years and had not responded to the available treatment options. The researchers zapped a 6mm length of trigeminal nerve, just 2 to 3mm from the root, using a maximum radiation dose of 73.06 Gy. The patients were then monitored regularly after the procedure, for an average of just under 12 months. Complete data were available for 16 patients, 14 of whom obtained either partial or complete relief from their symptoms. The average time before symptom relief occurred was just under two months, but varied from three weeks to six months. Four patients relapsed after the procedure, between three and 18 months later. No patient experienced major complications as a result of the procedure, and only two patients reported any sensory side effects. See: >"Cyberknife radiosurgery in treating trigeminal neuralgia" by Bryan M Lazzara et al. Journal of NeuroInterventional Surgery (2012). doi:10.1136/neurintsurg-2011-010125
FDA approves trial of Celution System (Cytori Therapeutics) for CMI Cardiology Page
Cytori Therapeutics has received an Investigational Device Exemption (IDE) approval from the FDA to begin the ATHENA trial using its Celution System. ATHENA will investigate the use of the Celution System to treat a form of Coronary Heart Disease, Chronic Myocardial Ischemia (CMI). The IDE application was originally submitted to the FDA in December 2011. The trial will enroll up to 45 patients with no-option CMI who have limited therapeutic options. It will evaluate a variety of clinical and functional outcomes, including safety, peak oxygen consumption (mVO2), and clinical outcomes at 12-months.
Phase III Trial of MDV 3100 (Medivation/Astellas) in Prostate Cancer patients shows positive results Oncology Page
Researchers have presented positive results on all efficacy endpoints from the Phase III AFFIRM trial of the investigational drug MDV 3100, from Medivation and Astellas, in men with Prostate Cancer previously treated with chemotherapy. The results, presented at the 2012 Genitourinary Cancers Symposium, show that men taking MDV 3100 lived for a median of 18.4 months, compared with 13.6 months for men taking placebo. MDV 3100 also met all secondary endpoints, including radiographic progression-free survival (8.3 versus 2.9 months; PSA declines of 50% or greater were more common in the MDV 3100 group than in the placebo group (54.0% versus 1.5%; and MDV 3100 was found to be well tolerated. The data was presented by Howard I. Scher, chief, Genitourinary Oncology Service at Memorial-Sloan Kettering Cancer Center.
